Skip to main content

Cutting-Edge Covid Treatments Owe Development to Carter-Era Law

By May 26, 2020News
NewImage

NewImage

The most promising Covid-19 treatments and vaccines being explored right now were made possible by a little-known law that encourages licensing agreements between private pharmaceutical companies and government-funded researchers.

Treatments such as Gilead’s remdesivir, Ridgeback Biotherapeutics’ EIDD-2801 drug, and Moderna’s vaccine candidate were all achieved through public-private partnerships that didn’t exist before the Bayh-Dole Act in 1980.

image:  A magnified coronavirus is displayed on a desktop computer monitor during coronavirus patient sample detection tests in the virology research labs at UZ Leuven university hospital in Leuven, Belgium, on Feb. 28, 2020.

Photographer: Geert Vanden Wijngaert/Bloomberg

 

{iframe}https://news.bloomberglaw.com/pharma-and-life-sciences/cutting-edge-covid-treatments-owe-development-to-carter-era-law?context=search&index=1{/iframe}
 

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.